Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 38 citations in OpenAlex.

1. Oseltamivir aziridines are potent influenza neuraminidase inhibitors and imaging agents.Proceedings of the National Academy of Sciences of the United States of America · 2026
   Article
2. Molecular dynamics study on the effect of the N1 neuraminidase double mutant G147R/H274Y on oseltamivir sensitivity.RSC advances · 2024
   Article
3. Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.Viruses · 2021
   Review
4. An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac.PloS one · 2018
   Article
5. A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.Open forum infectious diseases · 2017
   Review
6. Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.Journal of virology · 2015
   Article
7. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.Journal of virology · 2015
   Article
8. Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility.PloS one · 2015
   Article
9. Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.Antimicrobial agents and chemotherapy · 2014
   Article
10. A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.Antimicrobial agents and chemotherapy · 2014
    Article
11. Increased virulence of neuraminidase inhibitor-resistant pandemic H1N1 virus in mice: potential emergence of drug-resistant and virulent variants.Virulence · 2013
    Article
12. Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.Protein & cell · 2013
    Article
13. I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses.PloS one · 2013
    Article
14. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.Influenza and other respiratory viruses · 2013
    Review
15. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.Antimicrobial agents and chemotherapy · 2012
    Article
16. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.PloS one · 2012
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

11 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as